A Phase 3 interventional study of carvedilol MR and atenolol in Hypertrophy, Left Ventricular, sponsored by GlaxoSmithKline. Completed at 78 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-12-16.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Hypertrophy, Left Ventricular with a site in United States — 7 open to participants now, 8 under way, none of them phase 3. Hypertrophy, Left Ventricular · United States.
Among the 38 studies in Hypertrophy, Left Ventricular with a site in United States, this one is the 4th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2005, is one of 5 in phase 3, and was the 5th registered.
162 studies on the registry are indexed under Hypertrophy, Left Ventricular; 28 are open to participants now.
Browse Hypertrophy, Left Ventricular studies →7 of the 38 studies in Hypertrophy, Left Ventricular with a site in United States are open now. Recruiting first, the newest first:
Lexeo Therapeutics · Sites in United States
Ages 6+
eMyosound SAS · Sites in United States
Ages 60+ · Healthy volunteers
Rocket Pharmaceuticals Inc. · Sites in United States, Germany, Italy and 1 more country
Ages 8+ · Men only
Brigham and Women's Hospital · Sites in United States
Ages 18–75
Wake Forest University Health Sciences · Sites in United States
Ages 7–18 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Hypertrophy, Left Ventricular studies recruiting now, 13 (65%) set no upper age limit and 2 (10%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 6 · Phase 4 7
First in 1996; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 287 is above the median of 100 across 97 interventional studies indexed under Hypertrophy, Left Ventricular.
Median enrollment 94 across the 26 interventional studies, 138 across the 12 observational. Of the 28 that completed or were terminated, 9 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 38 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 1 study filed under Hypertrophy, Left Ventricular — fewer than ten, so there is no comparison to draw.
3 of the studies in Hypertrophy, Left Ventricular with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04752293Wake Forest University Health SciencesPediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE) | 2026-12 |
| NCT05388032Tulane UniversitySodium Lowering Vascular Effects Trial | 2026-12-31 |
| NCT05593055Brigham and Women's HospitalMineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension | 2027-04-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies in Hypertrophy, Left Ventricular with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to compare the effects of COREG MR (carvedilol modified release formulation) to atenolol on indices of left ventricular dimensions when added to standardized angiotensin converting enzyme (ACE) inhibition, and to the effect of ACE inhibition alone. Subjects with LVH (left ventricular hypertrophy) and hypertension will be studied. The primary endpoint will be the change in left ventricular mass index (LVMI) characterized by magnetic resonance imaging (MRI) following 12 months of treatment. Secondary endpoints include the change in LV (left ventricular) mass, LV wall thickness, diastolic left ventricular filling parameters, and left ventricular ejection fraction by echocardiographic methods at Treatment Month 12. Composite outcomes and individual event data will also be evaluated by treatment group.
A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination with and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Regression in Hypertensive Patients with Left Ventricular Hypertrophy (LVH).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Carvedilol controlled release (CR) 20 to 80 mg once daily (OD) plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study. (In the protocol, carvedilol CR was referred to as carvedilol modified-release \[MR\].)
Drug: carvedilol MR · Drug: lisinopril
Atenolol 50 to 100 mg OD plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study.
Drug: atenolol · Drug: lisinopril
Lisinopril 10 to 40 mg OD plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study.
Drug: lisinopril
Study drug
Also known as: Carvedilol controlled release or modified release
Comparator
Comparator
Also known as: carvedilol MR, atenolol
Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Magnetic Resonance Imaging (MRI) at Month 12
LVMI was measured by MRI at Baseline and after 12 months of treatment/Month 12. A reduction in left ventricular mass, calculated as LVMI, of 5 g/m\^2 was assumed to be clinically meaningful. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.
Time frame: Baseline and Month 12 (If Month 12 data were not available, the Last Observation Carried Forward [LOCF] analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by MRI at Month 12
LVMIH was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. LV mass depends on body size. One method of determining whether an individual has LV hypertrophy relates LV mass to height raised to a power of 2.7.
Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
Model-adjusted Mean Change From Baseline in Left Ventricular (LV) Mass as Measured by MRI at Month 12
LV Mass was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.
Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Echocardiography at Month 12
LVMI was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.
Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by Echocardiography at Month 12
LVMIH was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.
Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was available)
Model-adjusted Mean Change From Baseline in LV Mass as Measured by Echocardiography at Month 12
LV Mass was measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.
Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
Mean Change From Baseline in LV Filling Parameters as Measured by MRI at Month 12
LV filling parameters, LV E-Volume and LV A-Volume, were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. These filling parameters represent the volumes of blood filling the ventricle during the passive filling phase (E-volume) and the active filling phase caused by atrial contraction (A-volume).
Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by MRI at Month 12
LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. The ejection fraction is the fraction of the blood volume available at the end of diastole that is pumped out of the ventricules during systole.
Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
Model-adjusted Mean Change From Baseline in LV End Systolic and Diastolic Volumes and Ejection Fraction as Measured by Echocardiography at Month 12
LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.
Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
Model-adjusted Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Month 12
Systolic and Diastolic BP were measured at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.
Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF analysis, which includes data collected on or after Month 9 of treatment to Month 12 of treatment, was used)
Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed B-type Natriuretic Peptide (BNP) at Month 12
BNP concentration (picagram per milliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (mean change on log scale) -1) \[Change is the Month 12 value (or value after 12 months of treatment) minus the Baseline value\].
Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used
Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed C-Reactive Protein (CRP) at Month 12
CRP concentration (milligrams per deciliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent (mean change on log scale) - 1). \[Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.\]
Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)
Percentage Change From Baseline in Log Transformed Lipid Parameters at Month 12
Plasma lipid concentrations (milligrams per deciliter) were measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent(mean change on log scale) - 1). \[Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.\]
Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)
Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed Albumin Creatinine Ratio (ACR) at Month 12
Urinary ACR (micrograms per milligram) was determined at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (exponent (mean change on log scale) - 1. \[Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.\]
Time frame: Baseline and Month 12 (If Month 12 data were not available, the LOCF was used)
| Milestone | Carvedilol CR | Atenolol | Lisinopril |
|---|---|---|---|
| Started | 91 | 100 | 96 |
| Completed | 53 | 68 | 53 |
| Not completed | 38 | 32 | 43 |
| Withdrew: Adverse event | 14 | 12 | 17 |
| Withdrew: Lost to follow-up | 6 | 3 | 7 |
| Withdrew: Consent withdrawn | 3 | 3 | 5 |
| Withdrew: Protocol violation | 1 | 2 | 0 |
| Withdrew: Lack of efficacy | 3 | 1 | 2 |
| Withdrew: Amendment 4: > month 12 | 5 | 7 | 5 |
| Withdrew: Woman of child-bearing potential | 2 | 0 | 2 |
| Withdrew: Incorrectly randomized | 0 | 0 | 2 |
| Withdrew: Non-compliance | 1 | 0 | 2 |
| Withdrew: Stopped study medication | 0 | 0 | 1 |
| Withdrew: Site closed study | 0 | 2 | 0 |
| Withdrew: Protocol amendment | 0 | 1 | 0 |
| Withdrew: Study medication not tapered | 0 | 1 | 0 |
| Withdrew: Subject left site location | 1 | 0 | 0 |
| Withdrew: Investigator not at site | 1 | 0 | 0 |
| Withdrew: Blood pressure not controlled | 1 | 0 | 0 |
LVMI was measured by MRI at Baseline and after 12 months of treatment/Month 12. A reduction in left ventricular mass, calculated as LVMI, of 5 g/m\^2 was assumed to be clinically meaningful. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.
| grams per meters squared (g/m^2) | Carvedilol CR | Atenolol | Lisinopril |
|---|---|---|---|
| Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Magnetic Resonance Imaging (MRI) at Month 12 | -6.34 ± 0.850 | -6.67 ± 0.756 | -7.94 ± 0.850 |
LVMIH was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. LV mass depends on body size. One method of determining whether an individual has LV hypertrophy relates LV mass to height raised to a power of 2.7.
| g/m raised to 2.7 (g/(m^2.7)) | Carvedilol CR | Atenolol | Lisinopril |
|---|---|---|---|
| Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by MRI at Month 12 | -3.19 ± 0.407 | -3.37 ± 0.361 | -3.98 ± 0.407 |
LV Mass was measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.
| grams (g) | Carvedilol CR | Atenolol | Lisinopril |
|---|---|---|---|
| Model-adjusted Mean Change From Baseline in Left Ventricular (LV) Mass as Measured by MRI at Month 12 | -13.74 ± 1.732 | -14.17 ± 1.540 | -17.17 ± 1.734 |
LVMI was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.
| grams per meters squared (g/m^2) | Carvedilol CR | Atenolol | Lisinopril |
|---|---|---|---|
| Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed (LVMI) by Body Surface Area as Measured by Echocardiography at Month 12 | -20.35 ± 4.027 | -20.06 ± 3.672 | -18.48 ± 3.998 |
LVMIH was measured by echogradiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.
| g/m raised to 2.7 (g/(m^2.7)) | Carvedilol CR | Atenolol | Lisinopril |
|---|---|---|---|
| Model-adjusted Mean Change From Baseline in Left Ventricular Mass Indexed by Height (LVMIH) as Measured by Echocardiography at Month 12 | -11.78 ± 2.292 | -12.51 ± 2.100 | -11.61 ± 2.280 |
LV Mass was measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.
| grams | Carvedilol CR | Atenolol | Lisinopril |
|---|---|---|---|
| Model-adjusted Mean Change From Baseline in LV Mass as Measured by Echocardiography at Month 12 | -45.76 ± 8.338 | -40.56 ± 7.645 | -38.58 ± 8.296 |
LV filling parameters, LV E-Volume and LV A-Volume, were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. These filling parameters represent the volumes of blood filling the ventricle during the passive filling phase (E-volume) and the active filling phase caused by atrial contraction (A-volume).
| milliliters (mL) | Carvedilol CR | Atenolol | Lisinopril |
|---|---|---|---|
| LV E-volume | 0.364 ± 2.2853 | 6.763 ± 2.3870 | -3.406 ± 2.8779 |
| LV A-volume | -0.513 ± 1.3624 | -0.565 ± 1.5154 | 1.088 ± 1.5630 |
LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by MRI at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value. The ejection fraction is the fraction of the blood volume available at the end of diastole that is pumped out of the ventricules during systole.
| milliliters (mL) | Carvedilol CR | Atenolol | Lisinopril |
|---|---|---|---|
| LV End Systolic Volume | -1.44 ± 1.578 | -4.29 ± 1.397 | -3.04 ± 1.581 |
| LV End Diastolic Volume | -2.86 ± 2.848 | -2.45 ± 2.522 | -7.45 ± 2.858 |
| LV Ejection Fraction | 0.08 ± 0.685 | 2.16 ± 0.607 | -0.01 ± 0.685 |
LV End Systolic and Diastolic Volumes and Ejection Fraction were measured by echocardiography at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.
| milliliters (mL) | Carvedilol CR | Atenolol | Lisinopril |
|---|---|---|---|
| LV End Systolic Volume | -3.38 ± 2.067 | -4.74 ± 1.892 | -5.34 ± 2.086 |
| LV End Diastolic Volume | -3.07 ± 3.389 | -3.64 ± 3.108 | -9.37 ± 3.420 |
| LV Ejection Fraction | 1.03 ± 0.751 | 2.33 ± 0.687 | 0.63 ± 0.756 |
Systolic and Diastolic BP were measured at Baseline and after 12 months of treatment/Month 12. Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.
| mmHg (millimeters of mercury) | Carvedilol CR | Atenolol | Lisinopril |
|---|---|---|---|
| Systolic blood pressure | -21.32 ± 1.755 | -21.12 ± 1.535 | -22.53 ± 1.708 |
| Diastolic blood pressure | -12.77 ± 1.103 | -14.05 ± 0.976 | -11.13 ± 1.117 |
BNP concentration (picagram per milliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (mean change on log scale) -1) \[Change is the Month 12 value (or value after 12 months of treatment) minus the Baseline value\].
| percentage of change | Carvedilol CR | Atenolol | Lisinopril |
|---|---|---|---|
| Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed B-type Natriuretic Peptide (BNP) at Month 12 | 51.7 (13.2 to 103.2) | 48.3 (13.0 to 94.7) | -39.1 (-54.3 to -19.0) |
CRP concentration (milligrams per deciliter) was measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent (mean change on log scale) - 1). \[Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.\]
| percentage of change | Carvedilol CR | Atenolol | Lisinopril |
|---|---|---|---|
| Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed C-Reactive Protein (CRP) at Month 12 | -10.63 (-27.41 to 10.02) | -3.22 (-18.82 to 15.38) | 2.70 (-15.88 to 25.37) |
Plasma lipid concentrations (milligrams per deciliter) were measured at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and calculated as 100 x (exponent(mean change on log scale) - 1). \[Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.\]
| percentage of change | Carvedilol CR | Atenolol | Lisinopril |
|---|---|---|---|
| Total cholesterol | 0.7 (-3.3 to 4.9) | -1.3 (-4.7 to 2.3) | -1.7 (-5.5 to 2.3) |
| Low-density lipid cholesterol | 0.0 (-6.5 to 7.0) | -4.0 (-9.6 to 1.8) | -2.7 (-9.0 to 4.1) |
| High-density lipid cholesterol | -4.3 (-7.7 to 0.7) | -4.7 (-7.7 to -1.6) | -1.5 (-4.9 to 2.1) |
| Triglycerides | 11.0 (2.0 to 20.9) | 7.1 (-0.7 to 15.4) | 6.2 (-2.4 to 15.5) |
Urinary ACR (micrograms per milligram) was determined at Baseline and after 12 months of treatment/Month 12. Percentage change from Baseline was based on log transformed data and was calculated as 100 x (exponent (exponent (mean change on log scale) - 1. \[Change in Baseline was calculated as Month 12 value (or value after 12 months of treatment) minus the Baseline value.\]
| percentage of change | Carvedilol CR | Atenolol | Lisinopril |
|---|---|---|---|
| Model-adjusted Ratio to Baseline as Percentage Change From Baseline in Log Transformed Albumin Creatinine Ratio (ACR) at Month 12 | -27.1 (-39.9 to -11.6) | -20.1 (-32.4 to -5.5) | -21.5 (-35.2 to -4.8) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Carvedilol CR | — | — | — |
| Atenolol | — | — | — |
| Lisinopril | — | — | — |
| Event | Carvedilol CR | Atenolol | Lisinopril |
|---|---|---|---|
| Atrial fibrillationCardiac disorders | 1/91 | 0/100 | 2/96 |
| DizzinessNervous system disorders | 0/91 | 0/100 | 2/96 |
| Transient ischemic attackNervous system disorders | 0/91 | 0/100 | 2/96 |
| Non-cardiac chest painGeneral disorders | 0/91 | 2/100 | 1/96 |
| Coronary artery diseaseCardiac disorders | 1/91 | 0/100 | 0/96 |
| DepressionPsychiatric disorders | 1/91 | 0/100 | 0/96 |
| Neuropathy peripheralNervous system disorders | 1/91 | 0/100 | 0/96 |
| Abdominal painGastrointestinal disorders | 0/91 | 0/100 | 1/96 |
| Acute coronary syndromeCardiac disorders | 0/91 | 0/100 | 1/96 |
| Chest painGeneral disorders | 0/91 | 0/100 | 1/96 |
| Event | Carvedilol CR | Atenolol | Lisinopril |
|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 8/91 | 5/100 | 16/96 |
| FatigueGeneral disorders | 6/91 | 16/100 | 5/96 |
| HeadacheNervous system disorders | 13/91 | 11/100 | 10/96 |
| DizzinessNervous system disorders | 13/91 | 8/100 | 6/96 |
| NasopharyngitisInfections and infestations | 6/91 | 9/100 | 8/96 |
| DiarrheaGastrointestinal disorders | 5/91 | 7/100 | 7/96 |
| Upper respiratory tract infectionInfections and infestations | 5/91 | 3/100 | 7/96 |
| Edema peripheralGeneral disorders | 6/91 | 7/100 | 5/96 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 3/91 | 7/100 | 0/96 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 6/91 | 3/100 | 4/96 |
| Age, Continuous(years) | Carvedilol CR | Atenolol | Lisinopril | Total |
|---|---|---|---|---|
| Mean | 56.6 ± 10.53 | 57.4 ± 10.95 | 55.9 ± 10.09 | 56.7 ± 10.52 |
| Gender(Participants) | Carvedilol CR | Atenolol | Lisinopril | Total |
|---|---|---|---|---|
| Female | 40 | 41 | 47 | 128 |
| Male | 51 | 59 | 49 | 159 |
| Race/Ethnicity, Customized(participants) | Carvedilol CR | Atenolol | Lisinopril | Total |
|---|---|---|---|---|
| African American/African Heritage | 17 | 26 | 17 | 60 |
| American Indian/Alaska Native | 0 | 1 | 1 | 2 |
| Asian | 2 | 1 | 0 | 3 |
| White/Caucasian | 67 | 67 | 72 | 206 |
| Arabic/North African Heritage | 1 | 0 | 1 | 2 |
| Mixed Race | 1 | 0 | 1 | 2 |
| Not Reported | 3 | 5 | 4 | 12 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Jan 2005, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisinopril
Hypertrophy, Left Ventricular →